NCT02348450

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 308 (estimated)
• Sponsor: Guangdong Association of Clinical Trials · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is aimed to evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer and to explore the reasonable first-line therapy for Chinese population. An open-label, multi-center study will be conducted with dynamic randomization of approximately 1:1 ratio with an estimation of 308 eligible participants.

Detailed description

evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer and to explore the reasonable first-line therapy for Chinese population. An open-label, multi-center study will be conducted with dynamic randomization of approximately 1:1 ratio with an estimation of 308 eligible participants.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Irinotecan	40mg
DRUG	Etoposide	5ml：0.1g
DRUG	Cisplatin	6ml：30mg

Timeline

• Start date: 2015-02-01
• Primary completion: 2017-02-01
• Completion: 2018-12-01
• First posted: 2015-01-28
• Last updated: 2016-12-05

Locations

20 sites across 1 country: China